Diane Tseng, MD, PhD
Dr. Diane Tseng is a medical oncologist at Fred Hutchinson Cancer Center in Seattle, Washington. She specializes in treating patients diagnosed with lung cancer, head and neck cancers, malignant pleural mesothelioma, and thymic cancer. She has been a leader in cancer immunology for over a decade, pairing each patient’s condition and unique goals with the most innovative treatments available to improve their outcomes and quality of life.[1]
Dr. Tseng believes that by harnessing the immune system in the form of immunotherapy, she can give every patient the best possible chance in their fight against lung cancer.
Education and Career
Dr. Tseng earned a Bachelor of Science degree in Biological Sciences at Stanford University and attended Stanford University’s School of Medicine for her medical degree. She completed an internship and residency in Internal Medicine at Massachusetts General Hospital, then returned to Stanford University School of Medicine to complete fellowship training in Medical Oncology. While there, she also earned a PhD in Cancer Biology.[1]
Today, in addition to her role as a physician at Fred Hutch Cancer Center, she is an Assistant Professor in the Division of Medical Oncology at the University of Washington School of Medicine and an Assistant Professor in the Clinical Research Division at Fred Hutch Cancer Center.
Awards
Dr. Tseng’s accomplishments in cancer research have led to her being awarded numerous prestigious awards, including:
- Conquer Cancer Foundation Young Investigator Award, 2018[1]
- Lung Cancer Research Foundation Award, 2018[1]
- Lung Cancer Specialized Programs of Research Excellence (SPORE) Career Enhancement Program[1]
- LUNGevity Foundation Lung Cancer Workforce Development Research Award (2023)[1]
She is currently the principal investigator in a phase II clinical trial titled, “Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung).” The trial is investigating how well novel treatment combinations work in participants with metastatic non-small-cell lung cancer who have not previously been treated.[3]
Her recent publications include:[4]
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, Jeon YJ, Tseng D, Liu C, Merghoub T, Neal JW, Wakelee HA, Padda SK, Ramchandran KJ, Das M, Plodkowski AJ, Yoo C, Chen EL, Ko RB, Newman AM, Hellmann MD, Alizadeh AA, Diehn M.Cell. 2020 Oct 15;183(2):363-376.e13. doi: 10.1016/j.cell.2020.09.001. Epub 2020 Oct 1.PMID: 33007267
- Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.Chiou SH, Tseng D, Reuben A, Mallajosyula V, Molina IS, Conley S, Wilhelmy J, McSween AM, Yang X, Nishimiya D, Sinha R, Nabet BY, Wang C, Shrager JB, Berry MF, Backhus L, Lui NS, Wakelee HA, Neal JW, Padda SK, Berry GJ, Delaidelli A, Sorensen PH, Sotillo E, Tran P, Benson JA, Richards R, Labanieh L, Klysz DD, Louis DM, Feldman SA, Diehn M, Weissman IL, Zhang J, Wistuba II, Futreal PA, Heymach JV, Garcia KC, Mackall CL, Davis MM. Immunity. 2021 Mar 9;54(3):586-602.e8. doi: 10.1016/j.immuni.2021.02.014.PMID: 33691136
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL.Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26.PMID: 22451913
- Searching for Synergy: Chemotherapy and Checkpoint Inhibitors.Tseng D, Gainor JF.Clin Cancer Res. 2022 Jun 1;28(11):2206-2208. doi: 10.1158/1078-0432.CCR-22-0335.PMID: 35323910
- New Immuno-oncology Targets and Resistance Mechanisms. Tokaz MC, Baik CS, Houghton AM, Tseng D. Curr Treat Options Oncol. 2022 Sep;23(9):1201-1218. doi: 10.1007/s11864-022-01005-8. Epub 2022 Aug 18.PMID: 35980521 Review.
- Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.Tseng D, Padda SK, Wakelee HA.J Thorac Oncol. 2018 Jun;13(6):741-744. doi: 10.1016/j.jtho.2018.04.008.PMID: 29793645
- Cancer stem cell-directed therapies: recent data from the laboratory and clinic.Park CY, Tseng D, Weissman IL.Mol Ther. 2009 Feb;17(2):219-30. doi: 10.1038/mt.2008.254. Epub 2008 Dec 9.PMID: 19066601
References
View All References
